Both JAK2‐mutated and CALR‐mutated MPN patients showed significantly higher surface expression of PD‐L1 on NSC and progenitor cells compared to normal stem and progenitor cells (Figures 3B and S5B). The gene discussed is JAK2; the disease is myeloproliferative neoplasm.